| P50 | author | Espen Molden | Q43075786 |
| P2093 | author name string | S W Syversen | |
| | E Lie | |
| | I C Olsen | |
| | B M Wollmann | |
| | C Gjestad | |
| | L L Mehus | |
| P2860 | cites work | A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma | Q33450215 |
| | Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin | Q33870649 |
| | 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans | Q34580565 |
| | Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics | Q35114057 |
| | Immunological response as a source to variability in drug metabolism and transport | Q35749503 |
| | Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis | Q36055358 |
| | Drug metabolism and variability among patients in drug response | Q36139862 |
| | Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. | Q36320257 |
| | Regulation of drug metabolism and disposition during inflammation and infection | Q36544874 |
| | Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem | Q36634077 |
| | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? | Q36802040 |
| | A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction | Q36948140 |
| | Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. | Q38225574 |
| | Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | Q40784945 |
| | 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin | Q43146767 |
| | Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects | Q43571907 |
| | Endogenous 4β-hydroxycholesterol-to-cholesterol ratio is not a validated biomarker for the assessment of CYP3A activity | Q43768274 |
| | 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians | Q43944775 |
| | Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study | Q45188059 |
| | Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? | Q46003084 |
| | Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol | Q46466256 |
| | Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. | Q46495913 |
| | Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo | Q46496009 |
| | CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels | Q46610452 |
| | Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach | Q47692758 |
| | Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer | Q80546801 |
| | Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis | Q83692598 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 42-49 | |
| P577 | publication date | 2016-11-05 | |
| P1433 | published in | Clinical and Translational Science | Q5133809 |
| P1476 | title | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State | |
| P478 | volume | 10 | |